@article{5b590052a88b4c23811fe8f89dce06ec,
title = "Immune checkpoint inhibitor-induced polymyalgia rheumatica",
keywords = "Disease model, Immune-related adverse event, Mimics, Paraneoplastic, PD-1 agonist, PD-1 inhibitor, Peresolimab, Polymyalgia rheumatica",
author = "Liew, {David F. L.} and Mackie, {Sarah L.} and Alice Tison and Sattui, {Sebastian E.} and Max Yates and Buchanan, {Russell R. C.} and Owen, {Claire E.}",
note = "Funding Information: MY reports advisory board fees for BioGen.SES is by the Bristol Myers Squibb Foundation Robert A. Winn Diversity in Clinical Trials Career Development Award. SES has received research funding from AstraZeneca and GlaxoSmithKline (clinical trials) and participated in consulting and advisory boards for Sanofi and Amgen (funds toward research support). SES has received speaker fees from Fresenius Kabi (funds toward research support). ",
year = "2024",
month = may,
doi = "10.1016/j.rdc.2024.02.001",
language = "English",
volume = "50",
pages = "255--267",
journal = "Rheumatic Disease Clinics of North America",
issn = "0889-857X",
publisher = "W.B. Saunders Ltd",
number = "2",
}